BUSINESS

Big 3 Generic Makers Log 7.2% Growth in 1st Half, Suffer Sluggish Japan Sales on Price Cuts, COVID-19: Jiho Tally

November 20, 2020
Japan’s top-three generic makers collectively recorded a sales rise of 7.2% in April-September, with most of its growth resulting from the acquisition of a Spanish generic maker by Towa Pharmaceutical earlier this year. In the home market, however, the three…

To read the full story

BUSINESS

By Yoshinori Sagehashi

On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…

With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…

Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Philip Carrigan

As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…